Four Major Clinical Trial Readouts To Watch Out For In Q2
Executive Summary
Four prominent drug candidates are expecting topline mid- or late-stage data over the next few months. With the help of Biomedtracker's Q2 Outlook Report, we take a look at the assets that could help validate some of the companies developing them, from oncology to psychiatry.
You may also be interested in...
Alnylam/Regeneron Face Crowded IgA Nephropathy Field, But Combinations Likely
Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: GSK pursues M&A to boost pipeline; US decision affects Alzheimer’s candidates; Boehringer Ingelheim’s hopes for Jardiance; Japan rebuilds generic supplies; and a look at key upcoming trial readouts.
Stealth Elamipretide NDA Tests Frontiers Of US FDA’s Flexibility In Rare Diseases
FDA wants another trial in ultra-orphan Barth syndrome, but could not identify a feasible design – so Stealth submitted the NDA anyways, based on a retrospective natural history control trial